According to a health agency in Austria, inoculations with a batch of AstraZeneca's COVID-19 vaccine have been halted as a precaution while authorities investigate the death of one person and the illness of another following the shots. One woman, 49, died as a result of extreme coagulation disorders, while another, 35, suffered a pulmonary embolism and is recovering, according to the study. A dislodged blood clot causes a pulmonary embolism, which is an acute lung disease.
The women were both nurses who worked at the Zwettl clinic, according to the Austrian newspaper Niederoesterreichische Nachrichten, broadcaster ORF, and the APA news agency. According to BASG, blood clotting is not one of the vaccine's known side effects. It was pursuing its investigation with vigour in order to rule out any potential connection.
According to him, trials and real-world experience have shown that the vaccine is safe and reliable, and it has been approved for use in more than 50 countries. AstraZeneca has said that it is in touch with Austrian authorities and will fully cooperate with the investigation.
The product was approved by European Union regulators at the end of January, stating that it was successful and safe to use, and the World Health Organization (WHO) classified it for emergency use in mid-February. The majority of adverse reactions observed in clinical trials were short-lived, and no blood clotting problems were identified. A safety evaluation of over 360,000 people who received the Astra vaccine in Germany between its launch in early February and February 26 found that adverse reactions were consistent with the safety profile reported in clinical trials.